median effective does
Conditions
Interventions
frailty group:The initial dose was 0.25 mg/kg with a dose gradient ratio of 1:1.1, if the patient s consciousness disappeared then the next patient s dose of cyclobenzaprine was adjusted downward by o
nonfrailty group:The initial dose was 0.3 mg/kg with a dose gradient ratio of 1:1.1, if the patient s consciousness disappeared then the next patient s dose of cyclobenzaprine was adjusted downward by
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
65 Years to 84 Years
Inclusion criteria
Inclusion criteria: 1) Age >= 65 years; 2) Physical status I-III of the American Society of Anesthesiologists ; 3) Body mass index (BMI) 15-28 kg/m2; 4) planned abdominal surgery under total intravenous anesthesia 5) Clinical Frailty Scale for Frailty Group (CFS>=4)
Exclusion criteria
Exclusion criteria: 1) known allergy to eggs, soy products, or test drugs (propofol, ciprofol, remifentanil, cis-atracurium, neostigmine, atropine); 2) History of central nervous system disease; 3) Patients with severe hypertension, diabetes mellitus or hepatic or renal dysfunction, heart failure; 4) Difficult airway; 5) significant respiratory circulatory dysfunction; 6) refusal to sign the informed consent form;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| median effective does; | — |
Secondary
| Measure | Time frame |
|---|---|
| ABP;BIS;HR; | — |
Countries
China
Contacts
Public ContactYuan Jingjing
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed